The next breakthrough? MSK’s Sadelain ties up with Fate on off-the-shelf CAR-Ts
Fate Therapeutics is teaming up with one of the star scientists at Memorial Sloan Kettering to start work on off-the-shelf T cell therapies, one of the hottest fields in the next-gen CAR-T field.
This morning the San Diego-based biotech announced that it will partner with Michel Sadelain, a key scientist at MSK who has played a prominent role in developing Juno’s personalized CAR-Ts.
To get started, Fate has in-licensed tech that centers on engineering pluripotent cell lines to make them effective for all targeted patients. The first wave of CAR-Ts centers on personalized therapeutics in which investigators extract immune T cells from patients, arm them with chimeric antigen receptors and then infuse them back into the patient to hunt down cancer cells. That approach has proved particularly effective for the front-wave hematologic programs now in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.